GLP-1 efficacy ~ bariatric-surgery-like + Medicare Bridge access → patients substitute drugs for surgery → structural bariatric-surgery volume decline → ISRG bariatric segment down (loser) / LLY obesity TAM up (winner)

GLP-1 weight-loss efficacy now approaches bariatric-surgery-like magnitudes (retatrutide 28.3%) and use is exploding, while a new Medicare GLP-1 Bridge Program (launched 2026-07-01, $50 copay, ~3.8M eligible) structurally expands the drug population — so patients substitute drugs for surgery and metabolic bariatric-surgery volume is in structural decline (−34.1% 2022→2024). ISRG confirms first-party that its US da Vinci bariatric cases fell high-single-digits 'impacted by rising GLP1 usage' (loser); LLY (~60% US obesity share, oral Foundayo) is the TAM winner.

• Step 3: Bariatric-surgery volumes stabilize or rebound in 2025–26 — e.g. GLP-1 discontinuation and weight regain drive a return to surgery.
• Step 1: GLP-1 durability, tolerability, or cost failures cap real-world substitution below the trial-implied efficacy.
• Step 4: ISRG stops attributing bariatric weakness to GLP-1 usage, or its bariatric cases re-accelerate.

• **GLP-1 durability is the substitution's Achilles heel.** If discontinuation → weight regain drives patients back to surgery, the bariatric decline could stabilize or partially reverse — the structural read assumes drug adherence holds.
• **Obesity is 90–95% untreated**, so bariatric surgery and GLP-1 are both growing the *treated* pool from a small base; the substitution is real at the margin but the surgery decline is partly a mix-shift within an expanding total, not pure cannibalization.
• **Bariatric is a small slice of ISRG.** Reading the ISRG short too hard overweights a minor segment; the coverage-cliff deferral is the larger near-term ISRG drag.

• **intuitive-surgical (ISRG) — bariatric segment is a structural headwind, but sized, not fatal.** US bariatric cases −HSD is first-party, and the decline is structural (drug substitution) not cyclical — but bariatric is a modest share of total da Vinci procedures, so this is a persistent drag on the growth rate rather than a thesis-killer. It compounds with the separate coverage-cliff drag (aca-subsidy-cliff-to-deferred-procedure-volume).
• **eli-lilly (LLY) — primary winner.** ~60% US obesity share, oral Foundayo, and the Medicare Bridge Program expanding a net-new population (two-thirds of oral-GLP-1 volume is new to therapy). This is the demand-side complement to the picks-and-shovels chain glp1-injectable-supply-chain-bottleneck.
• **Novo Nordisk (NVO) is the co-beneficiary** (Wegovy oral + injection) but is a foreign ADR — a less-clean US expression than LLY.
• **Device-maker read-across** (staplers/energy — MDT, JNJ Ethicon) exists but is not a US-pure-play trade; the cleanest short expression of the substitution is ISRG's bariatric segment.